EXPERIENCE OF USING METHOTREXATE IN A PATIENT WITH EARLY OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
https://doi.org/10.15690/pf.v10i2.654
Abstract
The article describes a case with a severe course of oligoarticular juvenile idiopathic arthritis with the development of contracture and destructive articular alterations. The successful use of methotrexate (15mg/m2 of body surface per week, subcutaneously) in a child with early arthritis (disease duration – less than 2 years) is described: 6 months after the therapy had started, acute inflammatory articular alterations, arthralgiae, morning stiffness terminated; in 12 months the range of motions in the affected joints recovered completely. The inactive disease phase and remission were registered in 6 and 12 months, accordingly. The remission has continued for 12 months.
About the Authors
T. V. Sleptsova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
E. I. Alexeeva
Scientific Center of Children’s Health, Moscow, Russian Federation
Sechenov First Moscow State Medical University, Russian Federation
Russian Federation
Russian Federation
T. M. Bzarova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
K. B. Isaeva
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
E. V. Mitenko
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
References
1. Cassidy J., Petty R., Laxer R. M., Lindsley C. B. Texbook of paediatric rheumatology, 6th еd. Philadelphia: Elsevier Saunders. 2010. 794 р.
2. Alekseeva E.I., Litvitskii P.F. Revmatoidnyi artrit. Etiologiya, patogenez. Klinika. Algoritmy diagnostiki i lecheniya [Rheumatoid Arthritis. Etiology, Pathogenesis. Clinic. Algorithms for Diagnosis and Treatment]. Moscow, Vedi, 2007. 359 p.
3. Kroot E. J. A., van Leeuwen M. A., van Rijswijk M. H. et al. No increased mortality in patient with rheumatoid arthritis: up to
4. years of follow–up from disease onset. Ann Rheum Dis. 2000; 59: 954–958.
5. Klinicheskie rekomendatsii. Revmatologiya. Pod red. E.L. Nasonova [Clinical Recommendations. Rheumatology. Edited by E.L.Nasonov]. Moscow, GEOTAR-Media, 2005. pp. 25–71, 120–140.
6. Beukelman T., Patkar N. M., Saag K. G., Tolleson-Rinehart S., Cron R. Q., Dewitt E. M., Ilowite N. T., Kimura Y., Laxer R. M., Lovell D. J., Martini A., Rabinovich C. E., Ruperto N. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care & Research. 2011; 63 (4): 465–482.
7. Fleischmann R. Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. Expert Opin Drug Saf. 2003; 2 (4): 347–365.
8. Hashkes P. J., Laxer R. M. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294 (13): 1671–1684.
9. Yokota S. Classification and treatment strategy for juvenile idiopathic arthritis. Therapy. 1999; 81: 766–772.
10. Tynjala P., Vahasalo P., Tarkiainen M., Kroger L., Aalto K., Malin M., Putto-Laurila A., Honkanen V., Lahdenne P. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011. Р. 70.
11. Visvanathan S., Wagner C., Marini J. C., Loveд D. J., Martini A., Petty R., Cuttica R., Woo P., Espada G., Gattorno M., Apaz M. T., Baildam E., Fasth A., Gerloni1 V., Lahdenne P., Quartier P.,
12. Saurenmann R., Travers S., Mendelsohn A., Xu S., Giannini E. H., Ruperto N. For the Paediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatric Rheumatology. 2010; 8: 24.
13. Alarcon G. S. Methotrexate: its use for the treatment of rheumatoid arthritis and other rheumatic disorders. In arthritis and allied conditions. A Text book of rheumatology, 13th Edition. Ed. W. J. Koopman. Baltimore, Philadelphia, London: Williams & Wilkins. 1997; 1: 679–98.
14. Cronstein B. N. The mechanism of action of methotrexate. Rheum Dis Clin North Amer. 1997; 23: 739–755.
15. Tambic-Bukovac L., Malcic I., Prohic A. Personal experience with methotrexate in the treatment of idiopathic juvenile arthritis. Rheumatism. 2002; 49 (1): 20–24.
16. Cassidy J. T. Outcomes research in the therapeutic use of methotrexate in children with chronic peripheral arthritis. J Pediatr. 1998; 133: 179–180.
17. Klein A., Kaul I., Foeldvari I., Ganser G., Urban A., Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res (Hoboken). 2012; 64 (9): 1349–56.
18. Giannini E. H., Brewer E. J., Kuzmina N. et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med. 1992; 326: 1043–1049.
19. Woo P., Southwood T. R., Prieur A. M. et al. Randomized, placebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthr Rheum. 2000; 43 (8): 1849–1857.
20. Silverman E., Mouy R., Spiegel L. et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005; 352: 1655–1666.
21. Kuz'mina N.N., Bryuer E., Shaikov A.V. et al. Klinich. revmatol. – Clinical rheumatology. 1994; 1: 3–7.
22. Albertioni F., Flato B., Seideman P. et al. Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics. Eur J Clin Pharmacol. 1995; 47 (6): 507–511.
23. Ruperto N., Murray K. J., Gerloni V. et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004; 50: 2191–2201.
24. Tukova J., Chladek J., Nemcova D. et al. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2009; 27 (6): 1047–1053.
25. Alsufyani K., Ortiz-Alvarez O., Cabral D. A. et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol. 2004; 31 (1): 179–182.
26. Kugathasan S., Newman A. J., Dahms B. B. et al. Liver biopsy findings liver in patients with juvenile rheumatoid arthritis receiving long-term, weekly methotrexate therapy. J Pediatr. 1996; 128 (1): 149–151.
27. Cron R. Q., Sherry D. D., Wallace C. A. Methotrexate-induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J Pediatr. 1998; 132 (5): 901–902.
28. Wallace C. A., Giannini E. H., Huang В., Itert L., Ruperto N. Childhood Arthritis Rheumatology Research Alliance (CARRA), Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) (2011), American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. 2011; 63: 929–936. Doi: 10.1002/acr.20497.
29. Baranov A.A., Nasonov E.L., Alexeeva E.I., Erdes Sh.F., Il'in A.G. Voprosy sovremennoi pediatrii – Current pediatrics. 2007; 6 (1): 6–8.
Review
For citations:
Sleptsova T.V., Alexeeva E.I., Bzarova T.M., Isaeva K.B., Mitenko E.V. EXPERIENCE OF USING METHOTREXATE IN A PATIENT WITH EARLY OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. Pediatric pharmacology. 2013;10(2):121-126. https://doi.org/10.15690/pf.v10i2.654
Views:
712
Email this article 